Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the biopharmaceutical company’s stock. Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada reaffirmed a sector […]

Leave a Reply

Your email address will not be published.

Previous post Booking Holdings Inc. (NASDAQ:BKNG) Receives $3,582.54 Average PT from Brokerages
Next post Crimson Wine Group (OTCMKTS:CWGL) Share Price Passes Above 50-Day Moving Average of $5.89